Anti-tumor necrosis factor (anti-TNFα) drugs (Infliximab, Adalimumab, and Etanercept) are a class of drugs that have been used worldwide for over 10 years to treat inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, juvenile arthritis, Crohn’s colitis, ankylosing spondylitis and psoriasis. They consist of biomarkers capable of binding TNFα and blocking the action of the TNFα that is responsible for the inflammatory state. However all patients that are treated with these therapeutics are not all responding to the treatment and among those who are responders, the level of response is variable from one individual to another, but also for the same individual over time.
Several mechanisms can explain this variability:
- Different physiopathologies that lead to other pathways other than the TNFα pathways.
- Inter and intra-individual fluctuations of the effective serum concentration of the biopharmaceutical for a given dosage. These fluctuations arise from several elements that can be intricately linked for example,
- Neutralization of the active site of the biopharmaceutical, through anti-drug antibodies (ADAb) given the immunogenic characteristic of these molecules.
- An acceleration of the clearance of the biopharmaceutical, independent from the presence of ADAb.
- A high clearance of the biopharmaceutical, independent from the presence of ADAb.
In order to determine a patients response to treatment with anti-TNFα drugs, a new in vitro diagnostic modality known as Theranostics has emerged with the objective to provide information with which to offer greater personalization of treatment. Theranostic tests are combined with a targeted biotherapy in order to predict or evaluate a patient’s response by measuring one or more biomarkers. Besides screening for disease, its purpose is to enable clinicians to establish the treatment best suited for each disease, check the results of this treatment over time, modify this treatment and even change it should that be necessary due to side effects or lack of effectiveness.
Lisa Tracker is an ELISA kit program designed to measure the individual or simultaneous dosage of prescribed drugs or anti-drug antibodies (ADAb). Lisa Tracker Kits include a complete range of assays that offer standardized protocols, ready to use reagents, flexible formats, adaptable to all automated platforms and results in 3 hours.
Click here to learn more about Theradiag and the Lisa Tracker assays